Hepatitis C Side Effect Management: Lauren Thomas, RN, NP-C with Liver Specialists of Texas
by Dr. Joe Galati on September 26, 2011
Lauren Thomas, RN, NP-C, discusses in the video the management of side effects associated with hepatitis C therapy. The triple therapy, which includes pegylated interferon, ribavirin and a protease inhibitor (either telaprevir or boceprevir) are discussed. This video is geared for patients, family members, and healthcare providers involved in the care of hepatitis C patients and their treatment. Proper management of the medication side effects if key to successful treatment, and clearance of the HCV virus. Your comments are welcomed, letting us know what additional topics you would like included in the educational series.
Also See Hepatitis C Drug Incivek (telaprevir); What are the side effects ?
Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch
WATERTOWN, Mass., Sept. 26, 2011 /PRNewswire/ --
Enanta Pharmaceuticals, Inc. announced today that its lead development candidate from its NS5A hepatitis C virus (HCV) inhibitor program, EDP-239, has been recognized on Windhover's list of the "Top 10 Most Interesting Infectious Disease Projects to Watch." EDP-239 was chosen by independent experts at Windhover Information and Herndon Company.
NS5A, a clinically-validated target, is a non-structural viral protein that is essential to viral replication. Research efforts have shown that targeting NS5A gives rise to profound antiviral activity, and as a result, this protein has emerged as an important target for antiviral drug development. Enanta's NS5A program and intellectual property estate in the HCV field were derived from its internal drug discovery efforts.
"Enanta appreciates Windhover's recognition of our EDP-239 program for HCV, which showcases the strength of our internal drug discovery efforts aimed against important infectious disease targets," said Jay Luly, Ph.D, president and chief executive officer, Enanta Pharmaceuticals. "We are on-track to initiate a Phase 1 clinical trial for EDP-239 in the coming months, following preclinical studies that demonstrated picomolar potency against multiple genotypes of the virus, an excellent safety profile and a preclinical pharmacokinetic profile amenable to once-a-day dosing in humans."
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive infectious disease opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."
About the Hepatitis C Virus
Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and there is an acute need for new therapies that are safer and more effective. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease and NS5A inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.
Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is developing novel protease, NS5A, nucleoside(tide) polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include overcoming resistance to superbugs, treating respiratory tract infections, and developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately held company headquartered in Watertown, Mass. Enanta's news releases and other information are available on the company's web site at http://www.enanta.com/.
For Enanta Investor Relations, please contact:Paul Mellett617-607-0761
For Enanta Public Relations, please contact MacDougall Biomedical Communications:Kari Watson508-647-0209 or firstname.lastname@example.org
SOURCE Enanta PharmaceuticalsBack to top
RELATED LINKS http://www.enanta.com/
Recruiting A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Images in Clinical Medicine
Porphyria Cutanea Tarda
Chih-Chieh Chan, M.D., and Sung-Jan Lin, M.D., Ph.D.
N Engl J Med 2011; 365:1128
September 22, 2011
A 51-year-old man with a history of heavy alcohol use, chronic hepatitis C virus (HCV) infection, and hepatic cirrhosis presented to his physician with an 8-month history of periorbital hair growth. On examination, healing crusts and scars were evident in sun-exposed areas. He described skin photosensitivity and intermittent painful blistering over the nape of the neck, the forearms, and the backs of the hands (Panel A).
The patient's urine had pink fluorescence under a Wood's lamp, suggesting the presence of uroporphyrin (Panel B, a urine sample from the patient [indicated by an asterisk] and one from a normal control subject [N] under white light; Panel C, the same two urine samples under ultraviolet A light). A diagnosis of porphyria cutanea tarda was confirmed when marked uroporphyrinuria was shown on laboratory analysis. Porphyria cutanea tarda results from decreased activity of the uroporphyrinogen decarboxylase enzyme. Although the mechanism is unknown, the sporadic form of the disease is strongly associated with chronic HCV infection. Facial hypertrichosis is common and may serve as a diagnostic clue.
Although treatment of the patient's chronic HCV infection was considered inadvisable by his hepatologist, low-dose oral hydroxychloroquine, skin photoprotection, and alcohol cessation successfully controlled the cutaneous eruptions within 6 months.
Chih-Chieh Chan, M.D.Sung-Jan Lin, M.D., Ph.D.National Taiwan University Hospital, Taipei,
New Hepatitis C Drugs
Published on Sep 19, 2011 by wdsutv
According to the Centers for Disease Control, an estimated 3.2 million americans have chronic Hepatitis C infections. The FDA recently approved two new drugs for treatment.
Rapid Immune Test Cuts HIV Care Drop-Outs
By eliminating bottlenecks, a rapid immune system test sharply cut the proportion of people who dropped out of HIV care before starting treatment, researchers reported.
Old, diseased organs no barrier to donation
by: Marianne Betts
From: Herald Sun
September 26, 2011 12:00AM
ORGANS from old and diseased donors are increasingly being transplanted into gravely ill Australians.
The oldest donor last year was 84, and record numbers of organs are being transplanted from donors with cancer, diabetes and hepatitis, the Australian and New Zealand Organ Donation Registry 2011 Report reveals.
Despite an increase in organ donations, 1600 Australians are awaiting a transplant and many will die before they get one.
Last year, half the nation's 309 donors had been smokers, 14 had cancer, 20 had hepatitis B, two had hepatitis C, 29 had diabetes and 86 had high blood pressure.
In Australia, hepatitis B and C, cancer and the arenavirus have been passed on through infected donor organs and recipients have died.
Nine livers were transplanted from donors with hepatitis B or C.
Austin Hospital liver transplant unit director Professor Bob Jones said while some recipients might not have had hepatitis, others already would have had the disease.
He said there was a risk of hepatitis being passed from donor to recipient through a transplant.
"It's all about balancing the degree of risk - you have to balance these risks versus the risk of dying waiting," he said.
"If a patient is dying in ICU and has 24 hours to live and the only donor has hepatitis B, we will discuss it with the family."
Some elderly donors were suitable - a dying 30-year-old woman received a 78-year-old's liver, and two or three years later, it was still working "beautifully", he said.
Royal Australasian College of Surgeons transplant surgery chair Jonathan Fawcett said each year the average age of donors was rising.
"In the mid-1990s, (surgeons) were reluctant to use organs retrieved from donors over 50, but now it's common to use organs from donors well into their 60s," Mr Fawcett said.
Victorian medical director of organ and tissue donation Dr Helen Opdam said: "Ten years ago, we would not entertain using organs from someone who was a heavy smoker or a heavy drinker. "Now we will, as long as they are functioning well."
Prescription for Pot - A Debate on the Merits of Medical Marijuana
The use of marijuana for medicinal purpose has been a hotly debated topic in the United States. While cannabis is still listed as an illegal narcotic under Federal Law, 16 states and the District of Columbia have statutes decriminalizing medicinal marijuana as a therapy for specific ailments. Recently, the American Medical Association released a report urging review of marijuana as a Schedule 1 controlled substance, noting that physicians should be protected from prosecution for recommending marijuana and that further studies should be conducted into marijuana’s use as medicine.To provide further insight on this controversy, MD Magazine Peers & Perspectives convened two leading experts in the field to debate the merits or lack thereof of medical marijuana: Joel W. Hay, PhD, professor of clinical pharmacology and pharmaceutical economics and policy at the Shafer Center for Health Policy and Economics in the School of Pharmacy at the University of Southern California, and Joseph I. Sirven, MD, professor and chairman of the department of neurology at the Mayo Clinic in Arizona. The panel was moderated by Peter Salgo, MD. This transcript has been condensed and edited for clarity and length...Continue Reading
Podcast: Dollars for Docs Update
by Minhee ChoProPublica, Sep. 19, 2:44 p.m.
ProPublica’s Charles Ornstein, Tracy Weber and Dan Nguyen join the podcast this week to talk about their recently updated Dollars for Docs database – a project tracking big pharma’s payments to physicians.
ProPublica recently published a major update to our Dollars for Docs news application  – a database tracking money physicians have received from some of the pharmaceutical industry’s largest companies to promote their products.
Currently, the database lists $761.3 million in payments from 12 companies, which account for about 40 percent of U.S. sales. But in 2013, all drug and medical device companies will have to disclose what they are paying doctors for promotional talks, consulting, research, meals and more. Until then, ProPublica’s Dollars for Docs team – Charles Ornstein, Tracy Weber and Dan Nguyen – hope their project will shed some light on the industry’s ties to physicians. They join the podcast this week to explain the technical complexity of this project, why pharmaceutical companies enlist physicians to promote their products to begin with, and why patients have a right to know this information.
Click Below To Listen Or Read Transcript
UK-Man arrested over Nurofen contamination
Detectives investigating how packs of Nurofen Plus were found to contain antipsychotic and anti-epileptic drugs are questioning a man in custody.
Scotland Yard said the suspect, 30, from Bromley in south London, was arrested on Friday on suspicion of contamination of goods. He is being held in a south London police station.
Reckitt Benckiser, the drug's manufacturer, recalled the product on August 26 and halted distribution after discovering five boxes contained other companies' medicines.
It estimated some 250,000 packets were still in customers' hands.
Four of the affected boxes were found to contain the antipsychotic drug Seroquel XL 50mg and one packet contained Pfizer's anti-epileptic medication, Neurontin, in 100mg capsules.
The Met's Specialist Crime Directorate (SCD), which tackles serious and organised crime, is leading the probe and has been examining the entire production line of the drug as part of the inquiry.
AP IMPACT: Hospital drug shortages deadly, costly
By LINDA A. JOHNSONAP Business Writer
TRENTON, N.J. (AP) - A drug for dangerously high blood pressure, normally priced at $25.90 per dose, offered to hospitals for $1,200. Fifteen deaths in 15 months blamed on shortages of life-saving medications.
A growing crisis in the availability of drugs for chemotherapy, infections and other serious ailments is endangering patients and forcing hospitals to buy from secondary suppliers at huge markups because they can't get the medications any other way.
An Associated Press review of industry reports and interviews with nearly two dozen experts found the shortages - mainly of injected generic drugs that ordinarily are cheap - have delayed surgeries and cancer treatments, left patients in unnecessary pain and caused hospitals to give less effective treatments. That's resulted in complications and longer hospital stays.....
Nutrition experts out of the Harvard School of Public Health and Harvard Health Publications in Boston developed a blueprint for healthy eating that they call The Harvard Healthy Eating Plate
New On The Blog
Seeking Drugs to Fight and Prevent HCV Infection
Hepatitis C-Peregrine Phase II HCV Trial for Bavituximab
HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
Chronic Fatigue Syndrome—Science and Controversy
Healthy You-8 Most Common Mistakes Americans Make With Their Meds
Hepatitis C Side Effect Management: Lauren Thomas, RN, NP-C with Liver Specialists of Texas
HCV In The News
Check Out The Website
Hepatitis C New Drug Research And Liver Health
RSS Feed; Website Updates
Get Updates For HCV New Drugs Delivered By Email
DDW 2013 - May 18-21, 2013 - Orlando, FL
Digestive Disease Week - The conference will showcase the latest advances in GI research, medicine and technology in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery
View Media and DDW Updates
Hot Topics - May 2013
Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C
Hepatitis C: The Pace of Progress/Interferon-Free Treatment Still Searching
Interferon-free, treat-all approach cost effective, beneficial for chronic HCV
European Medicines Agency Validates Gilead's Marketing Application for Sofosbuvir for the Treatment of Hepatitis C
(On April 08) Gilead Submitted New Drug Application to U.S. FDA for Sofosbuvir (GS-7977) for the Treatment of Hepatitis C
Current and Future Therapies for Hepatitis C Virus Infection
If the past is a harbinger of the future, therapy for HCV infection will probably continue to advance at a brisk pace. Many additional potent agents are in the clinical pipeline, and interferon-free regimens are likely to dominate the HCV therapeutic landscape within the next 5 years.....
Summary EASL 2013 - New HCV DAAs on their way soon: what do the phase III studies tell us?
At this year's EASL in Amsterdam with over 9600 delegates the phase III study results for the two "second wave HCV protease inhibitors" faldaprevir and simeprevir each in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) for HCV genotype 1 patients were presented as well as the phase III findings for the polymerase inhibitor sofosbuvir again in combination with PEG-IFN/RBV for treatment of genotypes 1,4,5 and 6. In addition phase III results of the first interferon free combination of sofosbuvir with ribavirin for treatment of genotype 2 and 3 were presented....
HCV: Highlights from EASL 2013/Fred Poordad, MD
Best of the EASL 2013 on hepatitis C - webcast with Dr Andrew Muir
Hepatitis C in the United States Perspective
Care for hepatitis C is evolving rapidly, with increasingly effective and better-tolerated antiviral therapies being evaluated and approved for use. It's clear, however, that not everyone who would qualify for therapy has been tested and identified, referred for appropriate care, and offered or given the best therapy available. Furthermore, currently used antiviral drugs - pegylated interferon and ribavirin "base" plus either telaprevir or boceprevir - can cost more than $70,000 for a full course of therapy. It is expected that the new oral antiviral agents will be just as expensive, at least in the short term.
Hepatitis C Therapy Update 2013-What About Interferon-free Regimens?
U.S. FDA grants priority review to Simeprevir (TMC435) for combination treatment of genotype 1 chronic hepatitis C
AbbVie's ABT-450- Breakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen
Gilead Sofosbuvir and ledipasvir: Plans to initiate a third Phase 3 clinical trial with and without ribavirin
Cost will limit uptake of off-label Gilead/Bristol-Myers Squibb Hep C combo, despite best-in-class data
ViewPoints: New Hep C data validates Gilead's solo approach
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir (GS-7977) for the Treatment of Hepatitis C-- Sofosbuvir Would Form Basis of First All-Oral Regimen for HCV Genotype 2 and 3 Patients, and Interferon-Sparing Regimen for Genotype 1 Patients --
Anemia Top Side Effect of HCV Antivirals
Hepatitis C Virus Infection: Looking for Interferon Free Regimens
Review: NS5A Inhibitors in the Treatment of Hepatitis
VX-135/daclatasvir: Vertex signs agreement with Bristol-Myers for all-oral midstage studies for hepatitis C treatments
Simeprevir (TMC435) - Janssen Submits New Drug Application to U.S. FDA
Miravirsen- Hepatitis C drug goes after patients’ RNA
Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients
Hepatitis C - Presidio Collaboration with Boehringer Ingelheim for interferon-free Phase IIa clinical trial
Gilead hepatitis C drug sofosbuvir (GS-7977) meets goal of fourth late-stage study
EASL-Burden of Liver Disease in Europe: Looks at leading causes of cirrhosis and primary liver cancer in Europe
Gilead Announces SVR Rates from Two Phase 3 Studies of Sofosbuvir (GS-7977) for Hepatitis C
Potential IFN-Free Regimens For HCV
IDX184 and IDX19368 - Idenix drops development of hepatitis C drugs
Interferon free regimens for the “difficult to treat”: are we there?
Current Prospects for Interferon-free Treatment of Hepatitis C in 2012
Numerous other DAAs are in clinical development, and phases 2 and 3 trials are evaluating interferon-free combination DAA therapy. Interferon-free sustained virologic responses have now been achieved with combinations of asunaprevir and daclatasvir; sofosbuvir and ribavirin; sofosbuvir and daclatasvir; faldaprevir and BI207127; ABT-450, ritonovir and ABT-333; ABT-450, ritonovir and ABT-072; miracitabine, danoprevir and ritonavir; and alisporivir and ribavirin. Some drugs are genotype-specific in their activity, whereas others are pan-genotypic, and differential responses for the genotype 1 subtypes 1a and 1b have emerged with many DAA combinations. Viral breakthrough and resistance are important considerations for future trial design. The prospect of interferon-free combination DAA therapy for hepatitis C virus is now finally becoming a reality.
2013-Guide to Clinical Trials for People with Hepatitis C
Bristol-Myers to Hold Talks On Settling Claims of Hepatitis C Patients
Treat Now or Wait?
The debate rather to treat HCV now or wait is ongoing, in the journal "Liver International" factors which affect the decision to treat now or delay therapy are discussed. You can view the article here: Patients with HCV and F1 and F2 fibrosis: treat now or wait?
Lucinda K. Porter, RN Shares A Personal Experience: Starting 12 weeks of sofosbuvir, GS-5885, and ribavirin
Coming in September 2013
A second book authored by Lucinda K. Porter, RN: Hepatitis C Treatment One Step at a Time: Inspirational Readings and Practical Tips for Successful Hepatitis C Treatment
FREE FROM HEPATITIS C
Clinical Trial Updates
ClinicalTrials.gov: updated in the last 30 days
HCV PipelineHCV Advocate - News & Pipeline Blog
Chronic Hepatitis C Infection: Treat Now or Wait?
INCIVEK® (telaprevir)-Updates label after reports of a ‘small number of fatal skin reactions’
Vertex discloses Hep C drug deaths
HCV Transplant Studies GS-7977 Also Telaprevir & Boceprevir
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
Hepatitis C–What Are Your Treatment Choices: New Webinar
Setbacks in HCV Drug Development Highlight Uncertainties in Treat or Wait Decisions
So You Think You’re a Hepatitis C Expert
Back in July Clinical Care Options released part one of a three part online quiz containing 35 questions on hepatitis C, answered by nine world-renowned hepatology experts. In October CCO released part two of the series which included case scenarios from 11 leading international experts on hepatitis C, and today part three was released!
Idenix: FDA Places IDX19368 Hepatitis C Treatment on Clinical Hold
IDX184-Idenix hepatitis C drug put on partial hold
BMS halts the development of BMS-986094 due to patient death
BMS-986094-Bristol-Myers Sued Over Heart Damage In Hepatitis C Drug Trial
The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), will take place April 24 to 28 in Amsterdam, The Netherlands.
EASL Website - Press Room
EASL Abstract Search
Click here for a downloadable PDF version of the Abstract Book.
Tips For Viewing Hepatitis C Abstracts
Download now the ILC 2013 congress app and have full access to the scientific programme, posters, abstracts, floorplans and more!
EASL: Direct-acting antivirals now ready for prime time with promising alternatives on the way
AbbVie is a new, independent biopharmaceutical company composed of Abbott’s former proprietary pharmaceutical business
ABT-267, ABT-333-non- nucleoside, ABT-450/r
r = ritonavir
Faldaprevir/ (BI 201335)
MK-5172 and Daclatasvir
MK-5172 and Daclatasvir-Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial
CCO's independent conference coverage
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Long-term management of the successful adult liver transplant: 2012 practice guideline by the -AASLD
VA guidelines for management and treatment of HCV, published in the American Journal of Gastroenterology
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
Nonalcoholic Fatty Liver Disease (NAFLD)
New Clinical Practice Guideline Developed for Nonalcoholic Fatty Liver Disease
2012-New guidelines on the management of hepatocellular carcinoma (HCC).
These guidelines result from a joint collaboration between the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC).
EASL-April 2012 Revised Clinical Practice Guidelines on the Management of Chronic Hepatitis B
HCV Information and Educational Resources
Clinical Liver Disease -Digital Liver Disease Journal
This journal is an official digital educational resource from the American Association for the Study of Liver Diseases.
Visitors are able to view videos, full data, and download files in either HTML or PDF formats
View all issues here.
Projects In Knowledge
Offered at the site is a program series of HCV Video Case Vignettes. In the videos individual patient case studies are discussed, topics include side effects, drug-drug interactions, treatment duration, and outcome.
AASLD - Liver Learning
If you haven't yet explored the "Liver Learning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more.
Other HCV Sites:
These links will take you to the premier Hepatitis C sites and keep you informed with breaking news, clinical studies, new drugs, podcasts, newsletters, support, personal experiences, chat rooms, forums and more.
2012 Articles Of Interest
2012-New Antiviral Agents for Hepatitis C
This article describes the direct acting antivirals and host-targeted agents that have recently been approved or have been tested in HCV-infected patients and discusses their two current paths of clinical development: with or without interferon-α.
Standardization of Terminology of Virological Response in the Treatment of Chronic Hepatitis C
Protease inhibitors: Silver bullets for chronic hepatitis C infection?
Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
A significant increase in the number of patients with CHC to be treated is expected for 2012, with triple therapy regimens that are more complex. These expected developments represent a significant challenge and will stretch current resources.
The present Swiss Association for the Study of the Liver (SASL) expert opinion statement is not intended as guideline but shall provide some guidance on the management of CHC genotype 1 and the use of TPV and BOC
If you have just been diagnosed with hepatitis C or considering HCV therapy click here for easy to understand information.
Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs
Prescribing Information for INCIVEK including the Medication Guide.
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.
- (PPI-668) w-Faldaprevir (BI201335) and BI207127 (1)
- 2012 -168 Pages Of HCV FAQs (1)
- A 2013 Conference on Retroviruses and Opportunistic Infections (4)
- A Guide 2011-Management Of HCV (2)
- A Guide 2012-Guideline for Nonalcoholic Fatty Liver Disease (1)
- A-2012 EASL-AASLD Special Conference (2)
- A-2012 Update on the Diagnosis and Treatment of Hepatitis C (1)
- A-2012-New guidelines on the management of hepatocellular carcinoma (HCC). (1)
- A-Current status and future directions in the management of chronic hepatitis C (1)
- a-DDW 2011 Meeting (11)
- a-DDW 2012 meeting (21)
- a-DDW 2013 meeting (22)
- A-EASL 2011 Summary (1)
- A-EASL 2012 (79)
- A-EASL 2012 - Guidelines on the Management of Chronic Hepatitis B (1)
- A-EASL 2012 Index (1)
- A-EASL 2012 Internet Symposium (2)
- A-EASL 2012 Summary Of The Meeting (1)
- a-EASL 2013 (50)
- A-EASL 2013 Summary Of The Meeting (1)
- a-EASL 2013-abstract search (1)
- A-New targets for antiviral therapy (85)
- A-Patients who will remain untreated in the era of triple therapy (1)
- AASLD 2011 updated hepatitis C practice guidelines (2)
- AASLD 2012-63rd Annual Meeting (73)
- AASLD 2012-STC (1)
- AASLD Nov 2011 (60)
- AASLD Nov 2011-Pocasts-Videos-Webcasts (2)
- AASLD Nov 2011-Summary (1)
- AASLD Oct2010 (80)
- AASLD Oct2010-summary (1)
- ABT-267 (10)
- ABT-333-non- nucleoside (11)
- ABT-450 (9)
- ABT-450/r (20)
- ABT-450/r and ABT-072 (4)
- ABT-450/r plus ABT-333 (8)
- Acai Berry Scam (1)
- acetaminophen (2)
- ACH-1625 (15)
- ACH-2684 (5)
- ACH-2928 (2)
- ACH-3102 (9)
- ACLF (1)
- acupuncture (2)
- acute HCV (4)
- acute HCV-when to begin therapy (1)
- acute liver failure (1)
- addiction (15)
- Adherence to therapy (13)
- ADI-PEG 20 (1)
- AIDS (2)
- alcohol consumption (13)
- alisporivir (4)
- alpha-fetoprotein (1)
- ALS-2200 (3)
- ALS-2200 (VX-135) (11)
- ALS-2200 and ALS-2158 (3)
- ALS2158 (1)
- amazing sunday (1)
- ANA598 (5)
- ANA598-setrobuvir (2)
- ANA773 (1)
- ANA958 (1)
- anemia (8)
- antidepressants (4)
- antioxidants (1)
- arthritis (4)
- ascites (9)
- asthma (1)
- Asunaprevir (1)
- autoimmune hepatitis (1)
- Avila Therapeutics™ (1)
- AVL-192 (2)
- bath salts-spice (12)
- Bavituximab (5)
- BCX5191 (2)
- BCX5191-withdrawn (1)
- Behind the Headlines (8)
- Behind the Headlines-Vaccine (1)
- Best Hospitals (5)
- BI 201335 and BI 207127 (10)
- BI 207127 (7)
- BILB 1941 (1)
- Bioartificial Liver (3)
- biological "devices" to program cells (1)
- Biopump (1)
- BioScience (2)
- biosimilars (6)
- BIT225 (2)
- BL-8020 (2)
- blood safety (2)
- blood scandal (3)
- bms-650032 (6)
- BMS-650032 (Asunaprevir) BMS-790052 (Daclatasvir) (10)
- BMS-650032 and BMS-790052 (5)
- bms-790052 (18)
- bms-790052-declatasvir (10)
- BMS-986094-INX 189 halted (8)
- BMS-986094-INX 189 on hold (7)
- boceprevir (98)
- Boceprevir FDA Transcript (1)
- boceprevir patient guide (1)
- boceprevir-drug assistance program (3)
- boceprevir-Medication Guide-Prescribing Info (1)
- boceprevir-victrelis (179)
- boceprevir-victrelis-Cost (1)
- boceprevir-victrelis-mericitabine w-SOC (1)
- Bowel (1)
- Brain (7)
- Caleco Pharma (1)
- Canada (2)
- cancer (14)
- cancerous growths gallbladder and/or the bile duct (1)
- CDC (4)
- CDC- World Hepatitis Day 2011 (1)
- CDC- World Hepatitis Day 2012 (4)
- Chat room (3)
- children treating HCV (15)
- chronic disease (2)
- chronic fatigue (16)
- chronic hepatitis c (2)
- chronic liver failure (2)
- chronic pain (3)
- cirrhosis (173)
- cirrhosis-complications (10)
- cirrhosis-Vibrio vulnificus-raw oysters (1)
- clinical trials (120)
- clinical trials-Pro-Con (4)
- coffee (22)
- Colloidal silver (2)
- colonoscopy (2)
- comorbidities HCV anti-viral treatment and disease (1)
- compensated cirrhosis (11)
- Complementary and Alternative Medicine (20)
- Counterfeit drugs (7)
- covalent inhibitor (2)
- Creating Functional Hepatic Tissue (1)
- Cryoglobulinemia (5)
- CTS-1027 (5)
- Cyclophilin Inhibitors (1)
- Daclatasvir (3)
- daclatasvir-peg/riba (3)
- Daclatasvir/Asunaprevir (3)
- daclatasvir/asunaprevir/BMS-791325 (5)
- Daily Consensus Interferon (1)
- Danoprevir (12)
- Danoprevir/Mericitabine (2)
- DEB025 (2)
- DEB025- alisporivir (4)
- decompensated cirrhosis (18)
- Dental (3)
- Depression (16)
- diabetes (101)
- diabetes-insulin resistance (8)
- Digestion (2)
- Direct-acting Antivirals (11)
- disease progression (11)
- donation (13)
- drug alerts (1)
- Drug Assistance Programs (5)
- Drug Resistance Test (1)
- drug shortages (1)
- dry eye (3)
- dyspepsia (1)
- EASL (59)
- Economic Burden HCV (2)
- ELAD® Bioartificial Liver (1)
- encephalopathy (28)
- endoscopy (1)
- Epidemic HCV (9)
- Epogen (4)
- ESLD (1)
- faldaprevir (9)
- faldaprevir/ (BI 201335) (24)
- faldaprevir/BI 207127 (1)
- fatigue (7)
- Fatigue-Cognitive Function-Sleep Quality (2)
- Fatty Liver (113)
- Fatty Liver-RP103 (1)
- FDA (69)
- fibromyalgia (7)
- Fluvastatin (2)
- Foodborne illness (16)
- G7128 (1)
- gallbladder (1)
- gallstones (9)
- gastritis (1)
- Gastroenterologist (1)
- geno1 (93)
- geno2 (50)
- geno3 (57)
- geno4 (29)
- geno5 (6)
- geno6 (11)
- genotypes;All (14)
- green tea (2)
- GS-5885 (4)
- GS-7977 now Sofosbuvir (75)
- GS-7977 now Sofosbuvir and simeprevir (TMC435) (6)
- GS-7977 now sofosbuvir / GS-5885 now ledipasvir (14)
- GS-7977 now Sofosbuvir Plus Riba (2)
- GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir (10)
- GS-7977 Plus Peg/Riba (3)
- GS-9190 (7)
- GS-9256 (6)
- GS-9451 (2)
- GSK2336805 (3)
- Gut Bacteria (1)
- H pylori (1)
- HALL OF SHAME (42)
- HALT-C (8)
- hav (6)
- hav vaccine (1)
- hbv (97)
- hbv vaccine (1)
- HCV Australia (6)
- hcv abstracts (231)
- HCV Awareness (70)
- HCV Awareness-screening strategies (20)
- HCV Baby Boomers (33)
- HCV cardiovascular disease (1)
- HCV diet (3)
- HCV Forum (1)
- HCV generics (1)
- HCV hypertension (1)
- HCV natural compounds (1)
- HCV neurocognitive function (1)
- HCV News (1336)
- HCV News-weekly rewind (20)
- HCV pregnancy (6)
- HCV Protease Inhibitors in Active Drug Users (1)
- HCV replication (3)
- HCV research (93)
- HCV Self-management (1)
- HCV symptoms (3)
- HCV tests (20)
- HCV tests-endoscope (1)
- HCV transmission FAQ (1)
- HCV Vaccine (24)
- HCV vaccine GI-5005 (7)
- HCV Vaccine-TG4040 (MVA-HCV) (2)
- HCV Worldwide (29)
- HCV Worldwide Asia Australia Egypt (2)
- HCV Worldwide-Europe Canada Israel (1)
- HCV Your Health (3)
- HCV-autoimmune diseases (1)
- HCV-Breast Cancer Risk (1)
- HCV-Editorial (12)
- HCV-Education (56)
- HCV-elderly (3)
- HCV-Insulin resistance (11)
- HCV-Statins (7)
- HCV/HBV/HIV special populations (1)
- Health Reform (3)
- Health Reform-Insurance (4)
- Healthy you (30)
- hemochromatosis (1)
- HepaFat™ (1)
- Hepatitis-related Renal Disease (1)
- hepatocyte cell transplantation (1)
- hepatologist (1)
- hepatoSys Virtual Liver Network (1)
- herb (32)
- herb-kava (2)
- HEV (3)
- History of HCV (3)
- HIV (115)
- HIV-children (3)
- hiv/hbv-coinfection (1)
- HIV/HCV (70)
- hot topic (9)
- HTAs-host-targeting agents (1)
- human genome (6)
- human interferon alpha lozenges (2)
- Idenix Reports Positive Interim Data for Hepatitis C Drug (1)
- IDX184 (21)
- IDX184-Discontinued (1)
- IDX19368-Discontinued (1)
- IDX19368-hold (2)
- IDX719 (9)
- if I had.. (9)
- IFNL 4 (1)
- IL-7(CYT 107) (1)
- IL28B (63)
- IL28B Test (2)
- immune system (9)
- IMO-2125 (6)
- Inflammation (3)
- Inflammation Liver (1)
- Inflammatory Bowel Disease (1)
- INFRADURE Biopump (1)
- Inspirational (25)
- Insurance (1)
- Insurance medicare (1)
- interferon (5)
- Interferon Free Combinations (114)
- Interferon lambdas (1)
- interferon-free therapies (5)
- Investment News HCV Drugs (22)
- INX 189 (13)
- IP-10 (1)
- ITX-5061 (1)
- Joint pain (1)
- Just for fun (5)
- JX594/TG6006 (2)
- Lambda (7)
- ledipasvir (GS-5885) (4)
- Lichen Planus (5)
- List Peer-Reviewed Journals (2)
- Liver Abscess (2)
- liver biopsy (13)
- liver biopsy-necessary in all genotypes? (1)
- liver cancer (235)
- Liver cancer CF102 (2)
- Liver Cancer Treatment (73)
- liver cancer treatment-radiofrequency ablation (RFA) (2)
- Liver Cancer-HEAT Study of ThermoDox(R) (3)
- liver cancer-MCT-465 and MCT-485 (1)
- liver cancer/sorafenib (4)
- Liver Cysts (1)
- liver disease (16)
- Liver Fibrosis (99)
- liver function tests (12)
- liver health (68)
- Liver Injury Dietary Supplements (4)
- Liver Injury-Shark liver oil (1)
- Liver Pain (6)
- liver surgery (2)
- liver/anatomy (1)
- locteron (1)
- Locteron/interferon (2)
- lymphoma (3)
- M11-602 (1)
- marijuana (27)
- marijuana-based prescription drug (1)
- MBX-700 and MBX-701 (formerly SCH 900942 and SCH 900188) (1)
- Mediterranean diet (1)
- Men and HCV (4)
- microspheres (3)
- Milk thistle (23)
- Miracle Mineral Solution-MMS (1)
- Miravirsen (8)
- miRNAs (1)
- MK-5172 (11)
- MK-5172/peg/riba (1)
- MK-5172/Vaniprevir(MK-7009) (1)
- MK-7009 (4)
- monoclonal antibody GS-6624 (1)
- Morbidity-SVR (3)
- Mortality (12)
- myocardial infarction (1)
- myocarditis (1)
- nanoparticles (3)
- Nanotechnology (3)
- Natural leukocyte interferon alpha (Alfaferone) (1)
- Neutropenia HCV Treatment (4)
- new drugs (4)
- new hcv drugs (55)
- newly diagnosed (8)
- newsletters (46)
- Nitazoxanide (2)
- noni juice (1)
- noninvasive tests for fibrosis (39)
- nonresponders (8)
- NS5A inhibitor (2)
- NSAID (7)
- nucleoside inhibitors (1)
- null responders (10)
- occult hepatitis C virus infection (1)
- Off Topic (31)
- online pharmacy (1)
- Oral interferon (1)
- organ harvesting (11)
- organ trafficking (5)
- organ trafficking- U.S (1)
- organ-imported tainted tissue (1)
- Origin Of Hepatitis (1)
- Other Conditions Related To HCV (46)
- Other Conditions Related To HCV-Vasculitis (5)
- Other Health News (94)
- OTHER INFECTIOUS DISEASE (20)
- outsourcing clinical trials (3)
- outsourcing drugs (7)
- partial responders (3)
- Pediatric liver disease (1)
- Pegasys (10)
- Peginterferon (75)
- PegIntron (4)
- Peripheral Neuropathy (2)
- PF-05095808 (1)
- Pharmaceuticals (137)
- Pink eye-Sty-and other eye conditions (1)
- platelets (3)
- polymerase inhibitor (16)
- Porphyria Cutanea Tarda (PCT) (2)
- Post Treatment Symptoms (1)
- PPI-383 (1)
- PPI-461 (3)
- PPI-668 (3)
- primary biliary cirrhosis (PBS) (1)
- probiotics (1)
- procrit (4)
- prognostic test:response to therapy (1)
- promacta (1)
- prostate cancer (1)
- protease inhibitor (33)
- protease inhibitor- (NS3/4A) Drug Resistance Test (2)
- PSI-7977 (24)
- PSI-7977 and PSI-938 (1)
- PSI-7977-TMC435 (3)
- PSI-7977/ Daclatasvir-(BMS-790052) (1)
- PSI-938 (6)
- PSI-938-Halted (1)
- Pulmonary fibrosis (1)
- Quackery (10)
- Questions About HCV (4)
- rash (10)
- recall (25)
- regeneration (6)
- regenerative Medicine (15)
- relapse (8)
- resistance to protease inhibitors (16)
- response-guided therapy (4)
- RG7128 (9)
- ribavirin (25)
- Ritonavir (1)
- rituximab (2)
- salt (4)
- SB 9200 (1)
- scientists grow human livers in laboratory (7)
- SCY-635 (5)
- SCY-641 (1)
- Seasonal Flu Vaccine (9)
- selenium (2)
- setrobuvir (1)
- side effects (66)
- side effects-direct-acting antivirals (18)
- side effects-eyes (7)
- side effects-telaprevir (3)
- silibinin (4)
- silymarin (4)
- Simeprevir (15)
- Simeprevir/Samatasvir (IDX719) (1)
- SIR-Spheres microspheres (2)
- Small fiber neuropathy (2)
- sofosbuvir and ABT-450 (1)
- Sorafenib (6)
- sovaprevir (3)
- Sovaprevir (Formerly ACH-1625) (5)
- Sovaprevir/ACH-3102 (2)
- sphincter of Oddi (3)
- spleen (6)
- SPONTANEOUS CLEARANCE (12)
- Standardization of Terminology of Virological Response (1)
- Starting HCV Treatment (71)
- STAT-C (3)
- stem cell lawsuit (2)
- stem cell tourism (7)
- stem cell-diabetes (1)
- stem cells (77)
- stem cells-pluripotent (2)
- stem-cell-derived liver tissue model (1)
- supplements (16)
- support (45)
- support-hotline (5)
- Surgery in liver disease (2)
- svr (70)
- SVR-Mortality (4)
- svr-pitavastatin (Livalo) (1)
- svr-rapid response (1)
- SVR24-SVR12-SVR4 (9)
- Tattoos (2)
- telaprevir (125)
- Telaprevir FDA Transcript (1)
- telaprevir medication guide (1)
- telaprevir patient assistance (3)
- telaprevir prescribing information (1)
- telaprevir with VX-222 (20)
- telaprevir-incivek (209)
- telaprevir-incivek-Cost (3)
- Tenofovir (2)
- Terry's nails (1)
- TG4040 (2)
- Thalidomide (1)
- The natural history of hepatitis C (2)
- Therapy-over the age of 65 (1)
- TheraSphere (1)
- Thrombocytopenia (4)
- Thrombocytopenia-Promacta (1)
- thrombosis (3)
- thyroid (11)
- Timeline Hepatiits (1)
- TMC278 for HIV (1)
- TMC435 (26)
- TMC435 (Simeprevir) (27)
- TMC435-BMS-790052 (3)
- TMC647055 (3)
- TMC647055 and IDX719 (1)
- TMC649128 (4)
- toxicity (25)
- transmission (66)
- Transmission clinical setting (86)
- Transmission clinical setting-Government Report 2012 (1)
- Transmission of HCV Through Transplanted Organs (2)
- transmission-needlestick (2)
- transplant (163)
- transplant tourism (7)
- Transplant- Telaprevir/Boceprevir (3)
- transplant-certican (1)
- Transplant-GS-7977 now Sofosbuvir (1)
- transplant-HCV recurrence (2)
- transplant-IL28B (1)
- transplant-MELD (6)
- Triad Prep Pads (16)
- TT-034 (1)
- tylenol (11)
- upper abdominal pain (2)
- varices (14)
- video (259)
- video viral load test(PCR) (1)
- viral load (9)
- Virtual Liver (1)
- virus research (2)
- vitamin A (6)
- vitamin B12 (3)
- vitamin D (36)
- vitamin E (6)
- Vitamin E-TE/TCP supplements (1)
- vitamin k (1)
- vitamins (7)
- warning-black cohosh (1)
- weekend reading (42)
- wellness (52)
- what is hepatitis c (1)
- women (8)
- Xifaxan (1)
- XIX International AIDS Conference (4)
- zalbin (1)
- zinc (1)
- ► 2013 (502)
- ► 2012 (1293)
- AASLD-New Data Analyses for VICTRELIS™ (boceprevir...
- AASLD-New Data On BMS-790052 and BMS-650032 to be...
- AASLD-Vertex presentation of New Data; INCIVEK™and...
- AASLD-Acceptance of Four TMC435 Abstracts by Mediv...
- T.G.I.F Hepatitis News Ticker; Hep C Drugs:Bristol...
- Consider Hepatitis C Infection in Some Arthritis P...
- Liver Health and Wellness
- Hepatitis C patients likely to falter in adherence...
- Galectin-inhibiting therapeutics to treat fibrotic...
- Wednesday Hepatitis C News Ticker
- Telaprevir for Chronic Hepatitis C with Genotype 1...
- Liver cancer incidence lower in patients with nona...
- Hepatitis C virus resistance to protease inhibitor...
- AASLD 2011 Updated Hepatitis C Practice Guidelines...
- Research Yields Unprecedented Insight into Antivir...
- Seeking Drugs to Fight and Prevent HCV Infection
- Hepatitis News Ticker-Video;Side Effects Telaprevi...
- Hepatitis C-Peregrine Phase II HCV Trial for Bavit...
- HCV genotype 3 is associated with a higher hepatoc...
- Chronic Fatigue Syndrome—Science and Controversy
- Healthy You-8 Most Common Mistakes Americans Make ...
- Hepatitis C-Clinical trials
- Hepatic encephalopathy: Suspect it early in patien...
- Hepatitis C; The Big C In New York
- Wall Street-The Hepatitis C Race Is On
- FDA-Five more states had Listeria-tainted cantalou...
- Medistem Receives FDA Approval to Begin Clinical T...
- More Chinks in XMRV-Chronic Fatigue Link
- Marijuana Extract Might Help Prevent Chemotherapy-...
- Video-What Is Hepatitis C? HCV Therapy W-pegylated...
- Hepatitis C;John Franco's Campaign-Video
- AASLD-Beyond Telaprevir and Boceprevir: New Treatm...
- Hepatitis C: current management and emerging thera...
- Video-What is Chronic Pain?
- HCV News; Early virologic responses increases leve...
- European approval for hepatitis C drug, Telaprevir...
- Hepatitis C In The News; BMS-790052
- Signs of Poor Digestion-Bowel Problems
- How our Liver kills "killer cells"
- Monday HCV News Ticker;Patient Adherence to Hepati...
- BMS-790052-Positive results from a Phase II trial ...
- Hepatitis News Ticker- A Practical Guide for the U...
- Sitagliptin and Exenatide-Study suggests possible ...
- Treatment of Hepatitis C Iran Review-Boceprevir-V...
- Genotype 2b Hepatitis C Virus in Association with ...
- Hepatitis News Ticker;Does antiviral therapy preve...
- New Hepatitis C Drugs Offer Options but With Added...
- Pre-Liver Transplant Serum Ferritin Level Predicts...
- Hepatitis News Ticker
- Telaprevir-Incivek-Allows Shorter Hepatitis Therap...
- Merck puts faith in hepatitis, c. difficile drugs
- Hepatitis News Ticker;Coffee consumption reduces s...
- Chronic Hepatitis C Virus is Associated with More ...
- Hepatitis C-Interferon-Free Trial of PSI-7977 and ...
- Monday Hepatitis News Ticker
- Tekmira and Collaborators Demonstrate Efficacy of ...
- Americans mark 10th anniversary of September 11 at...
- ProPublica-Dollars for Docs Update
- HCV Weekend News Ticker;Japan-Telaprevir Improves ...
- The Hepatitis C Treatment Pipeline Report
- Hepatitis C Therapy Can Cause Mild Depression to S...
- HCV News Ticker;Anadys Hepatitis C Polymerase inhi...
- HCV News Ticker;Hepatitis C treatment gets persona...
- Benefits of Almonds for Individuals with Type 2 Di...
- Hepatitis C News Ticker; Preliminary Testing Of Ne...
- Hepatitis C PSI-7977 -Pharmasset Announces 91% SVR...
- Dramatic Changes in Hepatitis C Treatment Expected...
- Monday Hepatitis C News Ticker; HCV Genotype 6a
- Association between lichen planus and Hepatitis C
- Gilead Amends Study Design for GS 9190 four-drug r...
- Hepatitis C Neuropsychiatric symptoms-“brain fog”/...
- Watch-HIV/HCV-What Matters Most
- Telaprevir-Incivek/Boceprevir-Victrelis-Paying For...
- Dermatological side effects-Patient management in ...
- Chronic fatigue syndrome - In support of XMRV rese...
- New Options for HCV Treatment: Is Better Good Enou...
- New Sweat Sensors for Detecting Low Blood Glucose ...
- Video;Dr. Fauci on 30 years of AIDS
- TGI Friday HCV News:Adherence to Treatment for Hep...
- Hepatitis C in Minority Populations
- Trial Supports Addition of Telaprevir for HCV Geno...
- Sept 1 Hepatitis News Ticker
- ▼ September 2011 (83)
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ?
After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
- New HCV Drugs
- Keeping current on the potential arrival of new improved hepatitis C drugs. As once a hepatitis C patient myself (I successfully treated the virus with standard HCV therapy in 2000) I understand the difficult decisions and overwhelming fear that ensues after being diagnosed with this serious and life-changing disease. This blog serves as a starting point for information on the rapidly evolving number of new agents in development to treat hepatitis C. Tina